J&J’s DePuy Synthes agrees to acquire rights to MinMaxMedical’s Gemtrack RF tracking technology

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Johnson & Johnson unit DePuy Synthes agreed to acquire selective rights to develop, make, market MinMaxMedical’s Gemtrack RF tracking technology.
  • Deal targets joint reconstruction navigation and robotics, aiming to remove line-of-sight constraints tied to infrared camera-based tracking.
  • Scope covers the Joints portfolio, including shoulder, hip, knee, with planned integration into the VELYS enabling technology ecosystem.
  • Closing and rollout depend on product development milestones plus regulatory approvals; no financial terms were disclosed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.